Company Information

  

Address: 99 HAYDEN AVENUE, SUITE 230  
City: LEXINGTON 
State: MA 
Zip Code: 02421 
Telephone: 781-778-7720 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. We have an extensive patent portfolio of over 200 issued patents and 100 pending patent applications in the United States and worldwide, and covers various aspects of our PolyXen platform technology and advanced polymer conjugate technologies, as well as our proprietary biologic drugs and novel oncology drug candidates. We believe our portfolio positions us well for strategic partnership and commercialization opportunities. Our objective is to maximize opportunities to out-license assets from our portfolio in order to generate working capital to both build long-term stockholder value and provide us with the funding necessary to clinically develop our orphan oncology drug candidate pipeline through market launch.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-1.23NAN/E
06/2017-0.23NAN/E
03/2017-7.40NAN/E
12/2016-7.84NAN/E
09/2016-8.41NAN/E
06/2016-10.41NAN/E
03/2016--NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.34Total Liab/Total Assets0.23
Net Inc/Total Assets-2.58Total Liab/Inv Cap0.25
Net Inc/Inv Cap-2.84Total Liab/Comm Equity0.03
Pretax Inc/Net Sales-18.07Interest Coverage Ratio-73.30
Net Inc/Net Sales-18.07Curr Debt/EquityNA
Cash Flow/Net Sales-2.93LTD/EquityNA
SG&A/NetSales2.23Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover2.00Quick Ratio4.47
Inventory TurnoverNACurrent Ratio4.47
Inventory Day SalesNANet Rec/Curr Assets0.36
Net Sales/Work Cap0.46Inv/Curr AssetsNA
Net Sales/PP&E70.81  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.09 NA NA 3.00
Cost of Goods Sold 0.10 0.06 NA 0.00
Selling & Admin Exps 1.34 1.97 1.63 2.35
Operating Income -2.24 -2.90 -2.86 -0.06
Interest Exp 0.00 0.00 0.00 0.04
Pretax Income -2.26 -2.92 -2.87 -0.39
Other Income -0.01 -0.02 -0.01 -0.29
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -2.26 -2.92 -2.87 -0.39

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 0.76 2.40 4.39 4.11
Receivables - Total 0.04 0.00 0.00 3.00
Inventories - Total NA NA NA NA
Total Current Assets 2.05 3.83 6.21 8.34
Net Property, Plant & Equipment 0.03 0.04 0.04 0.04
Total Assets 14.64 16.44 18.83 20.97
Liabilities        
Accounts Payable 2.14 1.93 1.97 1.85
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 2.16 2.00 1.99 1.87
Long-Term Debt NA NA NA NA
Total Liabilities 5.08 4.93 4.93 4.80
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -150.38 -148.12 -145.20 -142.34
Treasury Stock -5.28 -5.28 -5.28 -5.28
Total Stockholders' Equity 9.55 11.51 13.90 16.17
Total Liabilities and Stockholders' Equity 14.64 16.44 18.83 20.97

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -1.64 -1.99 0.28 -4.62
Net Cash Provided by Investing Activities 0.00 -0.00 -0.01 -0.00
Net Cash Provided by Financing Activities 0.00 0.00 0.00 8.46

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.10-0.09--
12/20131.00-8.58--
12/20140.00-14.31--
12/20150.00-12.51--
12/20163.00-54.21-7.84
Growth Rates135.88----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1753353.84




Report Date : 12/4/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.